About Doctor
Dr. Benjamin Levy is a thoracic medical oncologist who also serves as the clinical director of medical oncology for the Johns Hopkins Sidney Kimmel Cancer Centre at Sibley Memorial Hospital and as an associate professor of oncology at Johns Hopkins University School of Medicine. He works out of Sibley Memorial Hospital’s Johns Hopkins Sidney Kimmel Cancer Centre.
Dr. Levy is a clinician scientist who is interested in novel immunotherapeutic treatments for patients with advanced lung cancer, as well as biomarkers that help identify those patients who are more likely to respond to such medicines. He specialises in thoracic malignancies such as non-small cell lung cancer, small cell lung cancer, thymic malignancies, and head and neck cancer.
Dr. Levy graduated from the Medical College of Georgia. He completed an internal medicine residency at Georgetown University Hospital, followed by a hematology/oncology fellowship at New York Presbyterian/Weill Cornell Medical Centre, where he received the Department of Medicine Research Fellow of the Year Award and the 2009 American Society of Clinical Oncology Young Investigator Award for his prostate cancer clinical research. Dr. Levy previously worked as an assistant professor at the Icahn School of Medicine, as the medical director of thoracic oncology for Mount Sinai Health Systems, and as the associate director of Mount Sinai Hospital’s Cancer Clinical Trials Office.
Dr. Levy has served on numerous American Society of Clinical Oncology (ASCO) committees and is currently an associate editor for the ASCO University Committee. He served on the editorial board of the Journal of Clinical Oncology for two years and is currently an ad hoc reviewer for additional publications such as Clinical Lung Cancer, The Oncologist, and Onco target. Dr. Levy was recently chosen as one of just 15 oncologists in the country to participate in the prestigious ASCO Leadership Development programme, which aims to discover and train future ASCO leaders. Dr. Levy also serves on the ALLIANCE Respiratory Committee, the IASLC Staging Committee, and the IASLC Career Development & Fellowship Committee in addition to his ASCO activities.
Hospital
Specialization
Procedures Performed
- Lung cancer
- Immunotherapy
Research & Publications
Becker DJ, Wisnivesky JP, Grossbard ML, Chachoua A, Camidge DR, Levy BP. “Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.” Clin Lung Cancer. 2017 Jan;18(1):e35-e40. doi: 10.1016/j.cllc.2016.08.008.
Levy BP, Rao P, Becker DJ, Becker K. “Attacking a Moving Target: Understanding Resistance and Managing Progression in EGFR-Positive Lung Cancer Patients Treated With Tyrosine Kinase Inhibitors.” Oncology (Williston Park). 2016 Jul;30(7):601-12. Review.
Levy BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA Jr, Hirsch FR. “Molecular Testing for Treatment of Metastatic Non-Small Cell Lung Cancer: How to Implement Evidence-Based Recommendations.” Oncologist. 2015 Oct;20(10):1175-81. doi: 10.1634/theoncologist.2015-0114.
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. “Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.” Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9.
Levy BP, Becker DJ. “The time for low-dose computed tomography screening is now: a medical oncologist perspective.” Oncology (Williston Park). 2014 Nov;28(11):964-6. No abstract available.
